PML targeting eradicates quiescent leukaemia-initiating cells

Nature

Volumn 453, Issue 7198, 2008, Pages 1072-1078

  Ito, Keisuke ^a,c   Bernardi, Rosa ^a,c   Morotti, Alessandro ^a,c   Matsuoka, Sahoko ^d   Saglio, Giuseppe ^e   Ikeda, Yasuo ^d   Rosenblatt, Jacalyn ^b   Avigan, David E ^b   Teruya Feldstein, Julie ^c   Pandolfi, Pier Paolo ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN;

BLOOD SYSTEM DISORDER; CANCER; CYTOLOGY; DISEASE TREATMENT; DRUG; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

EID: 44349166602     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07016     Document Type: Article

References (45)

1. Bruce, W. R. & van der Gaag, H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199, 79-80 (1963).
2. Huntly, B. J. & Gilliland, D. G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature Rev. Cancer 5, 311-321 (2005).
3. Scadden, D. T. Cancer stem cells refined. Nature Immunol. 5, 701-703 (2004).
4. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
5. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738-743 (2004).
6. Holtz, M., Forman, S. J. & Bhatia, R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 67, 1113-1120 (2007).
7. Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501 (2005).
8. Rowley, J. D. Anew consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293 (1973).
9. de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767 (1982).
10. Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
11. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
12. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
13. Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58-60 (2007).
14. Ghanima, W., Kahrs, J., Dahl, T. G. III & Tjonnfjord, G. E. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur. J. Haematol. 72, 441-443 (2004).
15. Cortes, J., O'Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204-2205 (2004).
16. Mauro, M. J., Druker, B. J. & Maziarz, R. T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk. Res. 28, 71-73 (2004).
17. Merante, S. et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90, 979-981 (2005).
18. Higashi, T. et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am. J. Hematol. 76, 275-278 (2004).
19. Bernardi, R. & Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Rev. Mol. Cell Biol. 8, 1006-1016 (2007).
20. Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165-170 (2002).
21. Wang, Z. G. et al. PML is essential for multiple apoptotic pathways. Nature Genet. 20, 266-272 (1998).
22. Bernardi, R. et al. PML inhibits HIF-1a translation and neoangiogenesis through repression of mTOR. Nature 442, 779-785 (2006).
23. Gurrieri, C. et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl Cancer Inst. 96, 269-279 (2004).
24. Scaglioni, P. P. et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126, 269-283 (2006).
25. Arai, F. et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149-161 (2004).
26. Pardal, R., Clarke, M. F. & Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nature Rev. Cancer 3, 895-902 (2003).
27. Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
28. Klaassen, C. D. Heavy metals and heavy-metal antagonists. In The Pharmacological Basis of Therapeutics (eds Hardman, J. G., Gilman, A. G. & Limbird, L. E.) 1649-1672 (McGraw-Hill, New York, 1996).
29. Aronson, S. M. Arsenic and old myths. R. I. Med. 77, 233-234 (1994).
30. Mathews, V. et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107, 2627-2632 (2006).
31. Soignet, S. L. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339, 1341-1348 (1998).
32. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89, 3354-3360 (1997).
33. 3-induced PML or PML/retinoic acid receptor a degradation. J. Exp. Med. 193, 1361-1371 (2001).
34. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006).
35. Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522 (2006).
36. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
37. Jørgensen, H. G. et al. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Exp. Hematol. 33, 1140-1146 (2005).
38. Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043-1052 (1999).
39. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173-10178 (2000).
40. Rego, E. M. et al. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193, 521-529 (2001).
41. Gurrieri, C. et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103, 2358-2362 (2004).
42. Wang, Z. G. et al. Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547-1551 (1998).
43. bcr-abl. J. Exp. Med. 194, 275-284 (2001).
44. Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nature Med. 12, 446-451 (2006).
45. Cross, N. C. et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br. J. Haematol. 84, 67-74 (1993).